A Retrospective Self-Controlled Study Evaluating the Prophylactic Effects of CACIPLIQ20 on Postsurgical Scars

Area of Science:

• Biomedical Engineering
• Dermatology
• Wound Healing Research

Background:

• CACIPLIQ20 is a medical device containing a heparan sulfate mimetic.
• It is designed to accelerate tissue healing by stabilizing matrix proteins and protecting growth factors.
• Previous studies suggested its efficacy in optimizing skin healing post-surgery.

Purpose of the Study:

• To evaluate the efficacy of CACIPLIQ20 in scar management following breast reduction surgery.
• To investigate a different administration regimen for CACIPLIQ20.
• To assess scar appearance using a blinded, standardized visual scale.

Main Methods:

• A randomized, self-controlled study involving 24 female patients undergoing breast reduction.
• Each patient served as their own control, with one breast treated with CACIPLIQ20 and the other with saline.
• Scar appearance was evaluated by six blinded independent raters using a global visual scar comparison scale.

Main Results:

• CACIPLIQ20 treatment resulted in a mean scar improvement of 15.2% compared to the control side (P = .016).
• Significant improvements (over 20% and 30%) were observed in a higher number of patients on the CACIPLIQ20-treated side.
• A single administration of CACIPLIQ20 on Day 0 showed the most promising trend for scar improvement.

Conclusions:

• CACIPLIQ20 demonstrates potential as an effective prophylactic scar therapy.
• A single application at the time of surgery appears to be an optimal regimen.
• The treatment showed no known adverse effects, supporting its safety profile.